---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-031942"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T06:04:00.640283+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioAtla adopts 1-for-50 reverse stock split via merger after Nasdaq policy reversal; delisting risk

## Summary
- Issued one share of super-voting Series A Preferred to pass reverse split (100M votes for), then redeemed it for $0.01.
- Board chose not to implement reverse split; Nasdaq said super-voting use now violates Rule 5640 without public notice.
- Entered merger for 1-for-50 reverse split; requires majority stockholder vote at special meeting.
- AIRC confirmed investment in Inversagen AI; BioAtla to receive $5M for 4.375% of SPV common units.
- Nasdaq compliance deadline Feb 2; company believes Nasdaq's delays and policy change were in error and harmful.

## SEC filing metadata
- accession: 0001193125-26-031942
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/bcab-20260126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-031942
- JSON: https://secwatch.observer/filing/0001193125-26-031942.json
- Plain text: https://secwatch.observer/filing/0001193125-26-031942.txt

## Source-grounded claims
- claim_id: 93eb4ea69bfc9e1d968d0720e98791c0be1396d6
  claim: BioAtla, Inc.: Filed Certificate of Elimination to remove Series A Junior Preferred Stock from the Amended and Restated Certificate of Incorporation (effective 2026-01-30).
  evidence_excerpt: On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.